mythics.azura.idevice.co.id

EQS-News: Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal

EQS-News: Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
   EQS-News: Marinomed Biotech AG / Key word(s): Study results
   Marinomed Biotech AG publishes remarkable results showing alleviation of
   allergic eye inflammation in patients treated with Tacrolimus eye drops in
   peer-reviewed journal

   08.10.2024 / 07:45 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Marinomed Biotech AG publishes remarkable results showing alleviation of
   allergic eye inflammation in patients treated with Tacrolimus eye drops in
   peer-reviewed journal

     • Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled
       formulation of Tacrolimus, are safe and effective in alleviating
       symptoms of allergic rhinoconjunctivitis
     • Data from phase II dose-finding clinical trial have been published in
       peer-reviewed Clinical Ophthalmology journal
     • Tacrosolv offers great potential in treatment of inflammatory diseases
       of the ocular surface

   Korneuburg, Austria, 08. October 2024 – Marinomed Biotech AG (VSE:MARI)
   has published clinical data from the phase II dose-finding clinical trial
   evaluating the efficacy of Tacrosolv eye drops in patients with allergic
   rhinoconjunctivitis in the peer-reviewed “(1)Clinical Ophthalmology”
   journal. The placebo-controlled allergen challenge trial assessed the
   efficacy and safety of two different doses of Tacrosolv. The results show
   that the higher dose of Tacrosolv eye drops (0.005% Tacrolimus)
   significantly reduced ocular symptoms of allergic conjunctivitis, and
   surprisingly, also the associated nasal allergy symptoms. Remarkably,
   these results were achieved with a dose that is 20-fold lower than that of
   the only Tacrolimus eye drop product currently on the market.

   Eva Prieschl-Grassauer, CSO of Marinomed, comments: “Tacrolimus is an
   immunosuppressive compound widely used to prevent organ rejection after
   transplantation or for treating inflammatory skin and eye diseases. In
   ophthalmology, there is currently only one marketed product in Asia in
   which Tacrolimus is used as a suspension. Due to its very low solubility
   in water and the associated very low bioavailability in the inflamed
   tissue, it takes days to weeks for the therapy to take effect. With our
   Marinosolv solubilization technology, we could significantly increase the
   solubility of Tacrolimus in a water-based formulation, thereby improving
   bioavailability, lowering the needed dose, and leading to a faster onset
   of action. The encouraging results of this clinical study show that
   Tacrosolv is a safe and effective treatment option for ocular
   inflammation. Tacrosolv has the potential to benefit a multitude of
   inflammatory eye diseases, where the currently limited treatment options
   create unmet medical need.”

   In the clinical trial, adults with a history of allergic conjunctivitis
   were randomized to either Tacrolimus or placebo treatment for 8 days.
   Allergic symptoms were induced by controlled allergen exposure on day 1
   and 8. During exposure, participants recorded ocular, nasal and
   respiratory allergy symptoms. The primary endpoint was the mean Total
   Ocular Symptom Score (TOSS) on day 8. Objective ocular safety parameters
   were assessed before, during and after exposure.

   On day 8, ocular symptoms (mainly redness and watery eyes) were reduced in
   participants receiving Tacrosolv compared to placebo treatment.
   Surprisingly, nasal symptoms (mainly itching and sneezing) were
   significantly reduced in participants treated with Tacrosolv already after
   the first application. This is an outstanding finding, as the only
   currently marketed eye drop formulation (Talymus® ophthalmic suspension
   0.1%, marketed in Asia) contains a 20-fold higher concentration of
   Tacrolimus. In conclusion, treatment with Tacrosolv at the dose and
   frequency studied is safe and significantly alleviates symptoms in
   participants suffering from allergic rhinoconjunctivitis.

   About Marinosolv®:

   Marinosolv® is an innovative technology platform that enables the
   solubilization and enhances the bioavailability of small molecules and
   peptides that are hardly soluble in aqueous formulations. Consequently,
   new treatments of a multitude of diseases can be envisaged. The use of the
   Marinosolv® technology can facilitate efficient drug delivery with a low
   systemic off-target activity. Existing drugs and off-patent active
   ingredients can be improved and re-patented as part of new formulations
   using Marinosolv®. Under the brand Solv4U, Marinomed provides Marinosolv®
   formulation development in technology partnerships for active ingredients
   at all stages of drug discovery and for lifecycle extension. For more
   information on Marinosolv® or Solv4U, please visit
   (2)https://www.solv4u.com. Scientific publications on Marinosolv® can be
   accessed in the “Immunology” tabs at
   (3)https://www.marinomed.com/en/news/scientific-publications.

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline and globally marketed therapeutics. The
   Company develops innovative patent-protected products in the therapeutic
   areas immunology and virology based on the platform Marinosolv® and the
   virus-blocking activity of Carragelose®. The Marinosolv® technology
   improves the solubility and bioavailability of hardly soluble compounds
   and is used to develop new therapeutics for autoreactive immune disorders.
   The virology segment includes Carragelose®-based over-the-counter (OTC)
   products to prevent and treat respiratory viral infections that are
   partnered in more than 40 countries. The Company is headquartered in
   Korneuburg, Austria, and is listed on the Vienna Stock Exchange
   (VSE:MARI). For further information, please visit:
   (4)https://www.marinomed.com.

   For further inquiries contact:

   Marinomed Biotech AG
   PR & IR: Lucia Ziegler
   T: +43 2262 90300 158
   E-Mail: (5)pr@marinomed.com
   E-Mail: (6)ir@marinomed.com

   Disclaimer

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forward-looking statements are only valid as of the date
   they are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
   trademarks of Marinomed Biotech AG. These trademarks may be owned or
   licensed in select locations only.

   ══════════════════════════════════════════════════════════════════════════

   08.10.2024 CET/CEST This Corporate News was distributed by EQS Group AG.
   www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 2003579


    
   End of News EQS News Service


   2003579  08.10.2024 CET/CEST

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0fecedee8150f3f0a4149cc07854b4d7&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2eeb8ec4c89acd0f1d74110ad9cc92&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=22703f0463e8f6df4d84a973309eef6c&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   5. mailto:pr@marinomed.com
   6. mailto:ir@marinomed.com

togel hari ini

data hk

togel hk

pragmatic play

Exit mobile version